Rachel Garcia, MD
Advanced Heart Failure and Transplant Cardiology · Cincinnati, OHNPI 1891016556
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Cvrx, Inc. at 56.9% of the total. 2025 is the largest year on record at $42,809, more than ten times the $472 reported in 2019. Among advanced heart failure and transplant cardiology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 450 payments — averaging $231.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$59K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23K
- Abbott$13K
- Impulse Dynamics (USA) Inc.$5K
- Abiomed$2K
- Bayer$1K
- plus $950 from 10 others
What the payments were for
- Consulting fees$41,00039%
- Speaking & faculty fees$31,15030%
- Travel & lodging$13,05913%
- Food & beverage$18,91418%
- Education$790%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 175 | $59,332 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 76 | $22,853 |
| Abbott | 137 | $12,942 |
| Impulse Dynamics (USA) Inc. | 17 | $4,936 |
| Abiomed | 11 | $1,886 |
| Bayer | 9 | $1,303 |
| Novartis | 9 | $244 |
| AstraZeneca | 2 | $143 |
| ZOLL Respicardia, Inc. | 1 | $140 |
| Paragonix Technologies, Inc. | 1 | $138 |
| Novo Nordisk | 4 | $100 |
| Biosense Webster, Inc. | 2 | $68 |
| Biotronik Inc. | 1 | $36 |
| Pfizer | 2 | $36 |
| Merck | 2 | $28 |
| Kestra Medical Technology Services, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$55,491
- LifeVest$21,210
- OPTIMIZER$8,826
- CARDIOMEMS$5,276
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$4,664
- Impella$1,713
- CardioMEMS HF System$504
- MitraClip$252
- HeartMate 3 Left Ventricular Dev$244
- OPTIMIZER SMART SYSTEM$224
- remede System$140
- Sherpacool$138
- Shipper$138
- Canister$138
- HeartMate Touch$138
- WAINUA$125
How this compares
$104,202 in reported general payments places this provider in the 90th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 327 | $401,769 |
| EliquisApixaban | 126 | $135,453 |
| JardianceEmpagliflozin | 109 | $116,142 |
| FarxigaDapagliflozin Propanediol | 68 | $72,487 |
| Torsemide | 136 | $4,807 |
| Spironolactone | 356 | $2,909 |
| Potassium Chloride | 32 | $2,880 |
| Eplerenone | 19 | $1,598 |
| Carvedilol | 210 | $1,489 |
| Amiodarone Hcl | 39 | $1,380 |
| Metoprolol Succinate | 127 | $1,129 |
| Isosorbide Dinitrate | 18 | $1,051 |
| Atorvastatin Calcium | 113 | $1,047 |
| Furosemide | 134 | $700 |
| Losartan Potassium | 77 | $563 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $244 | $401,769327 claims |
| PfizerEliquis | $36 | $135,453126 claims |
| AstraZenecaFarxiga | $143 | $72,48768 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Cincinnati
- Eugene ChungCincinnati$297K
- Ankit BhatiaCincinnati$141K
- Sateesh KesariCincinnati$101K
- Sitaramesh EmaniCincinnati$87K
- Gregory EgnaczykCincinnati$62K
- Santosh MenonCincinnati$30K
- Umama GorsiCincinnati$20K
- Stephanie DunlapCincinnati$9K
- Mahyar PourriahiCincinnati$8K
- Juliane ViereckeCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.